Pharmafile Logo

Video: Immuno-oncology therapies

June 3, 2016 | immuno-oncology 


Immuno-oncology therapies which harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. However, these therapies come with a very high price tag and currently only a few of these drugs have actually reached the market including Opdivo, Keytruda and Yervoy. In this video Director Sue Marett discusses the opportunities and challenges for new immuno-oncology therapies and outlines what these mean for pharma market research.

http://www.researchpartnership.com/news/2016/05/video-immuno-oncology-therapies/

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Guide

How to embrace behavioural science principles in healthcare MR

Article

A glimmer of hope for Alzheimer’s patients, but at what cost?

‘Smear Word’ campaign for Roche aims to break taboos and save lives

An all-female team at Mind+Matter has created a campaign for Roche that takes a tongue-in-cheek approach to tackle taboos about going for a smear test.

Video

Virtual Conference Live

Report

Digital Health Tools - Physician Trends

Webcast

Oncology landscape: How innovative market research methods can navigate you to success

Article:

The disparity of patient experiences with Crohn’s Disease in Europe and Japan

Research Partnership’s MedTech Division appoints two Directors

Chris Carles has joined as a Director in our Philadelphia office and Andrew Way as a Research Director in our UK office.

Webcast: Influencing HCP behaviours – Is now the perfect opportunity?

Putting behavioural science at the forefront of market research

Quantitative specialist joins Research Partnership, London

Global healthcare market research consultancy Research Partnership has appointed Roy Rogers as a Quantitative Director in their UK offices in London